69 MET immunoreactivity and poor prognosis Supplementary tables Supplementary table S1: Cell lines included in the MET antibody validation panel and their properties. Cell line Organism Organ Metastatic site Disease Morphology Expected p145MET status HeLa Homo sapiens Cervix Not applicable Adenocarcinoma Epithelial Positive (1)**, *** SK-BR-3* Homo sapiens Mammary gland; breast Pleural effusion Adenocarcinoma Epithelial Negative (2)*** HT-29 Homo sapiens Colon; colorectal Not applicable Adenocarcinoma Epithelial Positive (3)** LNCaP* Homo sapiens Prostate Left supraclavicular lymph node Carcinoma Epithelial Negative (4)**, *** PC3* Homo sapiens Prostate Bone Adenocarcinoma Epithelial Positive (4)**, *** DU145* Homo sapiens Prostate Brain Carcinoma Epithelial Positive (4)**, *** * Derived from metastatic site. ** p145MET is detected on cell lysate by means of western blot using a MET antibody directed against the extracellular domain of the protein. *** p145MET is detected on cell lysate by means of western blot using a MET antibody directed against the intracellular domain of the protein. 3
RkJQdWJsaXNoZXIy MTk4NDMw